Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia

[1]  M. Sattler,et al.  Drug resistance in mutant FLT3-positive AML , 2010, Oncogene.

[2]  M. Cragg,et al.  Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. , 2010, Blood.

[3]  I. Kerridge,et al.  A phase I study of anti-CD123 monoclonal antibody (mAb) CSL360 targeting leukemia stem cells (LSC) in AML. , 2010 .

[4]  N. Bartlett,et al.  Anti-CD30 Antibodies for Hodgkin Lymphoma , 2010, Current hematologic malignancy reports.

[5]  Christian Bailly,et al.  Strategies and challenges for the next generation of therapeutic antibodies , 2010, Nature Reviews Immunology.

[6]  David Jarjoura,et al.  CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. , 2010, Blood.

[7]  Merck Bioventures,et al.  Evolution of anti-CD20 monoclonal antibody therapeutics in oncology , 2010 .

[8]  Bob Löwenberg,et al.  FLT3 inhibition as a targeted therapy for acute myeloid leukemia , 2009, Current opinion in oncology.

[9]  M. Manz,et al.  The concerted action of GM-CSF and Flt3-ligand on in vivo dendritic cell homeostasis. , 2009, Blood.

[10]  T. Robak.  GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. , 2009, Current opinion in investigational drugs.

[11]  H. Rammensee,et al.  A bispecific single-chain antibody that mediates target cell-restricted, supra-agonistic CD28 stimulation and killing of lymphoma cells , 2009, Leukemia.

[12]  Holly M Horton,et al.  Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. , 2008, Cancer research.

[13]  K. Akashi,et al.  Differential Effects of the Type I Interferons α4, β, and ε on Antiviral Activity and Vaccine Efficacy1 , 2008, The Journal of Immunology.

[14]  H. Rammensee,et al.  Construction of optimized bispecific antibodies for selective activation of the death receptor CD95. , 2008, Cancer research.

[15]  Y. Sonoda,et al.  Flt3 ligand promotes myeloid dendritic cell differentiation of human hematopoietic progenitor cells: possible application for cancer immunotherapy. , 2007, International journal of oncology.

[16]  L. Old,et al.  Blood Dendritic Cells Generated With Flt3 Ligand and CD40 Ligand Prime CD8+ T Cells Efficiently in Cancer Patients , 2006, Journal of immunotherapy.

[17]  K. Konstantopoulos,et al.  Stimulation of Human Endothelium with IL-3 Induces Selective Basophil Accumulation In Vitro1 , 2006, The Journal of Immunology.

[18]  G. A. Lazar,et al.  Engineered antibody Fc variants with enhanced effector function. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Michael E. Williams,et al.  The Shaving Reaction: Rituximab/CD20 Complexes Are Removed from Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia Cells by THP-1 Monocytes1 , 2006, The Journal of Immunology.

[20]  D. Scheinberg,et al.  Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  D. Hicklin,et al.  Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice. , 2005, Cancer research.

[22]  H. Park,et al.  Functional and Phenotypic Characterization of Cord Blood-Derived Dendritic Cells , 2004 .

[23]  H. Hoffmann,et al.  Human mast cells express receptors for IL‐3, IL‐5 and GM‐CSF; a partial map of receptors on human mast cells cultured in vitro , 2004, Allergy.

[24]  H. Rammensee,et al.  A recombinant bispecific single‐chain antibody induces targeted, supra‐agonistic CD28‐stimulation and tumor cell killing , 2003, European journal of immunology.

[25]  K. Shitara,et al.  The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity* , 2003, The Journal of Biological Chemistry.

[26]  C. McPherson,et al.  Flt-3 Ligand: A Potent Dendritic Cell Stimulator and Novel Antitumor , 2002, Cancer biology & therapy.

[27]  H. Mckenna.  Role of hematopoietic growth factors/flt3 ligand in expansion and regulation of dendritic cells , 2001, Current opinion in hematology.

[28]  Y. Aizawa,et al.  Novel technique for the direct flow cytofluorometric analysis of human basophils in unseparated blood and bone marrow, and the characterization of phenotype and peroxidase of human basophils. , 1999, Cytometry.

[29]  L. Ginaldi,et al.  Levels of expression of CD19 and CD20 in chronic B cell leukaemias. , 1998, Journal of clinical pathology.

[30]  A. Zannettino,et al.  Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor tyrosine kinase. , 1997, Blood.

[31]  D. Sutherland,et al.  The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. , 1996, Journal of hematotherapy.

[32]  W. Wilmanns,et al.  Target cell‐induced T cell activation with bi‐ and trispecific antibody fragments , 1991, European journal of immunology.

[33]  Joseph Schlessinger,et al.  Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.

[34]  G K Lewis,et al.  Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product , 1985, Molecular and cellular biology.

[35]  R. Warnke,et al.  A unique human B lymphocyte antigen defined by a monoclonal antibody. , 1984, Hybridoma.